• Publications
  • Influence
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor and is hoped that it will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors. Expand
The 2007 WHO Classification of Tumours of the Central Nervous System
The fourth edition of the World Health Organization (WHO) classification of tumours of the central nervous system, published in 2007, lists several new entities, including angiocentric glioma,Expand
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.
Tumour fluorescence derived from 5-aminolevulinic acid enables more complete resections of contrast-enhancing tumour, leading to improved progression-free survival in patients with malignant glioma. Expand
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation and associated with prolonged PFS in the chemotherapy and radiotherapy arm. Expand
Embryonic stem cell-derived glial precursors: a source of myelinating transplants.
Transplantation in a rat model of a human myelin disease shows that ES cell-derived precursors interact with host neurons and efficiently myelinate axons in brain and spinal cord. Expand
Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein
Exome sequencing was performed and the NAB2-STAT6 fusion protein was detected in DNA of 8/10 meningeal HPC thereby providing evidence of close relationship of these tumors with peripheral SFT and it is demonstrated that this fusion can be rapidly detected by STAT6 immunohistochemistry which shows a consistent nuclear reallocation. Expand
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Molecular changes associated with gliomagenesis do not predict response to therapy in glioblastoma patients managed according to current standards of care and MGMT promoter methylation and IDH1 mutational status allow for stratification into prognostically distinct subgroups. Expand
NeuN: a useful neuronal marker for diagnostic histopathology.
The results indicate that NeuN immunoreactivity is a sensitive and specific neuronal marker in formalin-fixed, paraffin-embedded tissues, and may be useful in diagnostic histopathology. Expand
Gangliogliomas: An Intriguing Tumor Entity Associated With Focal Epilepsies
Findings support a dysontogenic origin from a glioneuronal precursor lesion with neoplastic, clonal proliferation of the glial cell population in gangliogliomas. Expand
Ammon's Horn Sclerosis: A Maldevelopmental Disorder Associated with Temporal Lobe Epilepsy
Its association with a lowered seizure threshold and an increased susceptibility for segmental cell loss in the hippocampus during the long course of the disease may constitute additional elements in a pathogenic cascade. Expand